通过新一类分子,膜活性免疫调节剂的天然产品缓解胰岛素耐药性
Elzbieta Izbicka1, Robert T Streeper1
1New Frontier Labs LLC, San Antonio, TX 78240, USA.
Pharmaceuticals (Basel, Switzerland)
|July 29, 2023
概括
像乙酸 (DEA) 这样的天然产品可以通过调节细胞膜来对抗胰岛素抵抗 (IR). 这些化合物被称为膜活性免疫调节剂 (MAIMs),为管理代谢疾病和改善葡萄糖吸收提供了一种新方法.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 胰岛素抵抗 (IR) 损害了细胞的葡萄糖吸收,导致了2型糖尿病等代谢疾病.
- 慢性炎症和受损的细胞信号传递与红外线发展有关.
- 红外线中的关键分子参与者包括等离子体膜蛋白,如胰岛素受体和葡萄糖载体4.
研究的目的:
- 提出一种新的生物活性分子类别,膜活性免疫调节剂 (MAIM),负责自然产品对IR的有益作用.
- 为了研究MAIM的作用机制,使用乙酸 (DEA) 作为代表性的例子.
主要方法:
- 文献综述和假设的制定.
- 对DEA对细胞等离子体膜流动性和细胞信号传输的影响的分析.
- 检查DEA对人类IR标记物的影响.
主要成果:
- 一些天然产品,包括脂质,和类,在改善IR方面表现有前途.
- 甲基乙酸 (DEA) 是一种中链脂肪酸,它增加了血的流动性,并影响了下游的信号传输.
- DEA已经证明了人类血糖,胰岛素和脂质水平的改善,表明增强的红外线标志物.
结论:
- 具有对IR有益影响的天然产品可能充当膜活性免疫调节剂 (MAIM).
- DEA的机制包括增强血流动性,从而改善细胞信号和红外线标记物.
- 这些发现表明,通过天然产品衍生化合物来缓解IR的新治疗途径.
相关概念视频
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
Oral Hypoglycemic Agents: Biguanides and Glitazones
234
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
208
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
208
Dipeptidyl Peptidase 4 Inhibitors
212
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
212
Insulin: Biosynthesis, Chemistry, and Preparation
431
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
431
Insulin: The Receptor and Signaling Pathways
1.3K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.3K


